Inflammation and the Heart

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Vanderbilt University
Sponsor:
Collaborator:
Arthritis Foundation
Information provided by (Responsible Party):
C. Michael Stein, Vanderbilt University
ClinicalTrials.gov Identifier:
NCT01589770
First received: April 24, 2012
Last updated: June 24, 2014
Last verified: June 2014
  Purpose

Studies have shown that people with rheumatoid arthritis (RA) have a higher rate of heart disease than people that do not have RA. we believe this is caused by the inflammation produced by RA.


Condition
Rheumatoid Arthritis

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Inflammation and the Heart

Resource links provided by NLM:


Further study details as provided by Vanderbilt University:

Primary Outcome Measures:
  • change in myocardial size and contractility measured by MRI [ Time Frame: before, and 6 months (24 weeks) after, starting disease modifying therapy ] [ Designated as safety issue: No ]

    For RA patients, a baseline MRI study will be done before starting disease modifying therapy for RA. Starting therapy is decided by the patient's rheumatologist, so is standard of care. Six months (24 weeks) later a second MRI study will be done to see if treatment changes myocardial size and contractility.

    For controls, baseline study only will be done.



Biospecimen Retention:   Samples With DNA

serum plasma DNA RNA


Estimated Enrollment: 345
Study Start Date: August 2012
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Groups/Cohorts
rheumatoid arthritis patients
People who have rheumatoid arthritis
controls
people who do not have RA or other inflammatory disease

Detailed Description:

Aim 1: We want to study people with RA to see if we can detect very early changes in their heart muscle and compare these results to people who do not have RA.

Aim 2: We want to study people with RA, who have at least 4 swollen joints, before and 6 months after starting a disease modifying therapy to see if there are any changes in the heart muscle on treatment.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

people with rheumatoid arthritis and people without rheumatoid arthritis or other inflammatory disease

Criteria

Inclusion Criteria:

  • Written informed consent
  • Age >= 18
  • RA only: meet American College of Rheumatology(ACR)criteria for Diagnosis of RA
  • Controls only: no evidence of RA or other inflammatory disease

Exclusion Criteria:

  • Previous or current heart failure or ischemic cardiovascular disease (eg stroke, myocardial infarction, angina, CABG, stent).
  • Atrial fibrillation.
  • Known structural or functional cardiac abnormality, including pulmonary htn.
  • Glomerular filtration rate < 60 ml/min.
  • Pregnancy or breastfeeding.
  • Unable to perform MRI (claustrophobia, unable to fit in magnet,pacemaker,defibrillator or non-MR safe implant).
  • Hypersensitivity to gadolinium.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01589770

Contacts
Contact: C. Michael Stein, MD 615-936-3420 michael.stein@vanderbilt.edu
Contact: Annette M Oeser, MLAS 615-322-3778 annette.oeser@vanderbilt.edu

Locations
United States, Tennessee
Vanderbilt Recruiting
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Vanderbilt University
Arthritis Foundation
Investigators
Principal Investigator: Charles Michael Stein, MD Vanderbilt University
  More Information

No publications provided

Responsible Party: C. Michael Stein, Dan May Professor of Medicine, Professor of Pharmacology, Assistant Director of the Division of Clinical Pharmacology, Vanderbilt University
ClinicalTrials.gov Identifier: NCT01589770     History of Changes
Other Study ID Numbers: 120314
Study First Received: April 24, 2012
Last Updated: June 24, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Vanderbilt University:
rheumatoid arthritis
inflammation

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Inflammation
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on September 18, 2014